Liraglutide and Exenatide in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes

<b>Background/Objective:</b> Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibit neuroprotective properties in preclinical models of Alzheimer’s disease (AD), reducing amyloid accumulation, neuroinflammation, and insulin resistance within the brain. However, clinical evidence regarding the...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Paula Santos, Alberto Souza Sá Filho, Vicente Aprigliano, Amanda G. Duarte, Natã Alegransi Ribeiro, Katia Marques Lombardo, James Oluwagbamigbe Fajemiroye, Artur Prediger Buchholz, Victor Renault Vaz, Gaspar R. Chiappa
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2026-01-01
Σειρά:	Pharmaceutics
Θέματα:	GLP-1 receptor agonists liraglutide exenatide Alzheimer’s disease mild cognitive impairment cognition
Διαθέσιμο Online:	https://www.mdpi.com/1999-4923/18/1/69
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!